Transcatheter single-access closure using Starway Neo Occluder successfully closed ventricular septal defects with 100% closure and no residual shunt or complications at one month in 2 patients.
Case Report (n=2)
No
Does transcatheter single-access closure using a Starway Neo Occluder safely and effectively close perimembranous ventricular septal defects?
The transcatheter single-access VSD closure technique via the right brachial artery using a Starway Neo Occluder is technically feasible and demonstrates a favorable early safety profile in selected patients.
Introduction Ventricular septal defect (VSD) is among the most prevalent congenital heart diseases, accounting for approximately 20%–30% of cases. Mainstay treatments encompass interventional closure and surgical repair. The conventional interventional approach necessitates puncturing both the femoral artery and vein to establish an arteriovenous circuit for device delivery. While markedly less invasive than open-heart surgery, this method carries inherent risks, including sheath compression challenges, conduction block, injury to valvular chordae tendineae, and vascular complications. Case description To enhance procedural safety while maintaining efficacy, our center pioneered a transcatheter single-access closure technique for VSD, performed under fluoroscopic and echocardiographic guidance in two patients. This “single” strategy proved successful in both instances. The procedures were well-tolerated, with patients achieving ambulation on the same day, experiencing stable perioperative periods, and demonstrating favorable early recovery outcomes. Immediate and one-month follow-up transthoracic echocardiography confirmed stable device position, with no evidence of residual shunt or new-onset valvular regurgitation. Conclusion These case reports preliminarily indicate that the transcatheter single-access VSD closure technique is technically feasible and demonstrates a favorable early safety profile. While limited in scale, the successful outcomes in these two cases suggest significant promise for broader clinical adoption. However, further validation through larger-scale studies and long-term follow-up is required to confirm its sustained efficacy and safety.
Huang et al. (Tue,) conducted a case report in perimembranous ventricular septal defect (n=2). Transcatheter single-access closure of ventricular septal defect using Starway Neo Occluder vs. None (case report) was evaluated on Successful closure of VSD without residual shunt or new valvular regurgitation at one-month follow-up. Transcatheter single-access closure using Starway Neo Occluder successfully closed ventricular septal defects with 100% closure and no residual shunt or complications at one month in 2 patients.